Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 / 2 Trial to Investigate The Safety and Tolerability of Single and Repeated Doses of hI-CON1™ Following Administration by Intravitreal Injection in Subjects With Neovascular Age-Related Macular Degeneration (AMD)

NCT01485588 is registered in ClinicalTrials.gov with Iconic Therapeutics, Inc. as lead sponsor.

NCT NCT01485588
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01485588 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 / 2 Trial to Investigate The Safety and Tolerability of Single and Repeated Doses of hI-CON1™ Following Administration by Intravitreal Injection in Subjects With Neovascular Age-Related Macular Degeneration (AMD)
Lead sponsor
Iconic Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
December 31, 2010
Completion date
March 31, 2012
Enrollment
18 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular age-related macular degeneration